Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has entered into a partnership with the Shanghai Institute for Biomedical and Pharmaceutical Technologies (SIBPT), formerly known as the Shanghai Institute of Planned Parenthood Research (SIPPR). The collaboration aims to enhance collaboration in scientific research and development, achievement translation, team building, and party building. The two parties will leverage their advantageous resources to innovate cooperation models, providing technical and intellectual support for the construction of strong disciplines, talent development, and the transfer and translation of scientific and technological achievements, thereby driving industrial technological innovation and upgrading. Financial details of the agreement were not disclosed.
SIBPT plays a significant role in the fields of population health and biomedicine, encompassing key common technologies, disruptive technologies, and major product research and development, application transformation, and technical services. The institute has established a comprehensive biopharmaceutical research and development innovation system, ranging from disease mechanism research and drug target discovery to candidate drug design and efficacy research, pharmacological toxicology research, preclinical safety evaluation, clinical cohort research, and post-launch introduction, promotion, and comprehensive evaluation of new products.
As a leading pharmaceutical company in both pharmaceutical industry and commerce in China, SPH has a business presence across various fields including pharmaceutical research and development, manufacturing, distribution, and retail. In recent years, driven by technological innovation, SPH has increased its research and development investment, absorbed social innovation resources, and is exploring innovative models of industry-university research alliances.- Flcube.com
